Journal
TRANSPLANT INTERNATIONAL
Volume 29, Issue 5, Pages 515-526Publisher
WILEY
DOI: 10.1111/tri.12659
Keywords
Epstein-Barr virus; good manufacturing practices; human cytomegalovirus; solid organ transplantation; T-cell therapy; virus-specific
Categories
Ask authors/readers for more resources
This article reviews the current state of T-cell therapy as therapeutic option for virus-associated diseases against the background of the most common viral complications and their standard treatment regimens after SOT. The available data of clinical T-cell trials in SOT are summarized. References to the hematopoietic stem cell transplantation are made if applicable data in SOT are not available and their content was considered likewise valid for cell therapy in SOT. Moreover, aspects of different manufacturing approaches including beneficial product characteristics and the importance of GMP compliance are addressed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available